81 related articles for article (PubMed ID: 9474189)
21. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
22. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
23. Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden.
Czene K; Hemminki K
J Urol; 2003 Apr; 169(4):1271-5. PubMed ID: 12629341
[TBL] [Abstract][Full Text] [Related]
24. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
25. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
26. Symptomatic local recurrence of prostate carcinoma after radiation therapy.
Leibovici D; Lee AK; Cheung RM; Spiess PE; Kuban DA; Rosser CJ; Shen Y; Yang Y; Chichakli R; Pisters LL
Cancer; 2005 May; 103(10):2060-6. PubMed ID: 15822114
[TBL] [Abstract][Full Text] [Related]
27. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy.
Kong L; Lu JJ; Hu C; Guo X; Wu Y; Zhang Y
Cancer; 2006 Sep; 107(6):1287-93. PubMed ID: 16909425
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
29. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
30. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
31. Primary causes of death after permanent prostate brachytherapy.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
[TBL] [Abstract][Full Text] [Related]
32. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
33. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
[TBL] [Abstract][Full Text] [Related]
34. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
35. The risk and prophylactic management of bladder cancer after various forms of radiotherapy.
Shirodkar SP; Kishore TA; Soloway MS
Curr Opin Urol; 2009 Sep; 19(5):500-3. PubMed ID: 19553822
[TBL] [Abstract][Full Text] [Related]
36. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
37. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
38. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer].
Heidenreich A; Ohlmann CH
Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
40. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]